Chemotherapy-Induced Changes in Plasma Amino Acids and Lipid Oxidation of Resected Patients with Colorectal Cancer: A Background for Future Studies
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25105300 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Roberto Aquilani und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Amino Acids, Antineoplastic Combined Chemotherapy Protocols, Fluorouracil. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Professional Dietetics S.p.A., Milano, Italy.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Previous studies have documented that FOLFOX and XELOX therapies negatively impact the metabolism of skeletal muscle and extra-muscle districts. This pilot study tested whether three-month FOLFOX or XELOX therapy produced changes in plasma amino acid levels (PAAL) (an estimation of whole-body amino acid metabolism) and in plasma levels of malondialdehyde (MDA), a marker of lipid hyper oxidation. Fourteen ambulatory, resected patients with colorectal cancer scheduled to receive FOLFOX (n = 9) or XELOX (n = 5) therapy, after overnight fasting, underwent peripheral venous blood sampling, to determine PAAL and MDA before, during, and at the end of three-month therapy. Fifteen healthy matched subjects (controls) only underwent measures of PAAL at baseline. The results showed changes in 87.5% of plasma essential amino acids (EAAs) and 38.4% of non-EAAs in patients treated with FOLFOX or XELOX. These changes in EAAs occurred in two opposite directions: EAAs decreased with FOLFOX and increased or did not decrease with XELOX (interactions: from p = 0.034 to p = 0.003). Baseline plasma MDA levels in both FOLFOX and XELOX patients were above the normal range of values, and increased, albeit not significantly, during therapy. In conclusion, three-month FOLFOX or XELOX therapy affected plasma EAAs differently but not the baseline MDA levels, which were already high.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
- Department of Biomedical Engineering of the Montescano Institute, Istituti Clinici Scientifici Maugeri IRCCS, 27040 Montescano, Italy.
- Department of Drug Sciences, University of Pavia, 27100 Pavia, Italy.
ORCID-Profile: Salvatore Corallo
Förderung
- Professional Dietetics S.p.A., Milano, Italy
Zitieren
APA
Aquilani, R., Brugnatelli, S., Maestri, R., Iadarola, P., Corallo, S., Pagani, A., Serra, F., Bellini, A., Buonocore, D., Dossena, M., Boschi, F., & Verri, M. (2024). Chemotherapy-Induced Changes in Plasma Amino Acids and Lipid Oxidation of Resected Patients with Colorectal Cancer: A Background for Future Studies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105300
Vancouver
Aquilani R, Brugnatelli S, Maestri R, Iadarola P, Corallo S, Pagani A, et al. Chemotherapy-Induced Changes in Plasma Amino Acids and Lipid Oxidation of Resected Patients with Colorectal Cancer: A Background for Future Studies. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105300
BibTeX
@article{Aquilani2024,
author = {Aquilani, Roberto and Brugnatelli, Silvia and Maestri, Roberto and Iadarola, Paolo and Corallo, Salvatore and Pagani, Anna and Serra, Francesco and Bellini, Anna and Buonocore, Daniela and Dossena, Maurizia and Boschi, Federica and Verri, Manuela},
title = {Chemotherapy-Induced Changes in Plasma Amino Acids and Lipid Oxidation of Resected Patients with Colorectal Cancer: A Background for Future Studies},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25105300}
}
EUVIMED